{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Blood Cancer Talks","title":"Episode 24. ASCO/EHA 2023 Special: Updates on CAR T-cell Therapy in Myeloma","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/a7f603c7\"></iframe>","width":"100%","height":180,"duration":2850,"description":"In this episode, we discuss the latest updates on CAR T-cell therapy in multiple myeloma, including the studies presented at ASCO and EHA 2023. Here are the show notes:\n1. For a primer on CAR T-cell therapy, listen to our episode aired on July 22nd 2022 with Dr. Surbhi Sidana: https://share.transistor.fm/s/efc4acf9\n2. RCTs of BCMA CAR T-cell Therapy in Early Relapsed Multiple Myeloma:\na) KarMMa-3 (ide-cel): https://pubmed.ncbi.nlm.nih.gov/36762851/\nb) CARTITUDE-4 (cilta-cel): https://pubmed.ncbi.nlm.nih.gov/37272512/\n3. Clinical trials of GPRC5D CAR T-cell therapy in multiple myeloma:\na) MCARH109 (MSKCC Trial): https://pubmed.ncbi.nlm.nih.gov/36170501/\nb) POLARIS Trial: https://pubmed.ncbi.nlm.nih.gov/36725117/\n3. Phase 1 UNIVERSAL trial of ALLO-715 in Multiple Myeloma:\nhttps://pubmed.ncbi.nlm.nih.gov/36690811/\n\n4. Anti BCMA/CD19 CAR T-cells with IMiD maintenance therapy in myeloma:\nhttps://pubmed.ncbi.nlm.nih.gov/36413381/\n\n ","thumbnail_url":"https://img.transistorcdn.com/sqlYzk0Oxhchi1Lmft_9Md8dG97D7hyy2rwRG7COuc0/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9zaG93/LzMyMDc4LzE2NTcz/MTQxMDUtYXJ0d29y/ay5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}